AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance databaseView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Absence of GS-6207 Phenotypic Resistance in HIV Gag Cleavage Site Mutants, Patient Isolates With Gag Polymorphisms, and Isolates With Resistance To Existing Drug ClassesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020HCV resistance associated variants following directly acting agent therapy failure- real life data from PolandView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI-experienced patients in ItalyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020TDR surveillance and clinically relevant resistance in Spain: 2019 updateView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolatesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020The effectiveness of the application of serological tests and laboratory indicators as part of RITA for the detection of recent HIV infectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020The quantification of HBeAg levels differ among the different phases of HBV infection, and can predict therapeutic outcome in the setting of immunosuppression driven HBV reactivation.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020A hybrid sequencing approach for accurate minority detection and resolving haplotype informationView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020A pan-genotypic nearly whole genome amplification approach of HCV by a simple two-step RT-PCR combined with parallel Oxford Nanopore and Illumina sequencing produce highly accurate long-range sequencesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020The Significance of M2BPGi Marker and CCC DNA in Unknown Etiology HepatitisView Abstract
